| Literature DB >> 29724508 |
Fei Gao1, Yifeng Jiang1, Guoxin Li2, Yanjun Zhou2, Lingxue Yu2, Liwei Li2, Wu Tong2, Hao Zheng2, Yujiao Zhang2, Hai Yu2, Tongling Shan2, Shen Yang2, Huan Liu2, Kuan Zhao2, Guangzhi Tong3.
Abstract
Porcine reproductive and respiratory syndrome (PRRS) and classical swine fever (CSF) are economically significant diseases that affect the swine industry worldwide. However, the current vaccination strategy, which uses two single live attenuated vaccines, can result in interference for each other. In addition, the universally used CSFV vaccine C-strain does not allow for differentiation of infected and vaccinated animals. In this study, rPRRSV-E2, PRRS virus (PRRSV) expressing CSF virus (CSFV) E2, was constructed by reverse genetics. The E2 gene of CSFV was inserted between ORF1b and ORF2 in the genome of the PRRS vaccine virus, HuN4-F112. A copy of transcriptional regulatory sequence 6 was inserted at the 3' terminal of the exogenous gene to produce CSFV E2 as a unique subgenomic mRNA transcript. The rPRRSV-E2 was stable for at least 25 serial cell passages. Single-shot intramuscular immunization of rPRRSV-E2 into pigs induced PRRSV-specific and CSFV-specific antibodies and fully protected pigs from lethal challenge with highly-pathogenic PRRSV and CSFV. These results demonstrate that a novel strategy for recombinant PRRSV production is effective, and suggest that rPRRSV-E2 is a promising live, virus-vectored vaccine against PRRS and a marker vaccine against CSF.Entities:
Keywords: CSFV E2; Recombinant PRRSV; Viral-vectored vaccine
Mesh:
Substances:
Year: 2018 PMID: 29724508 DOI: 10.1016/j.vaccine.2018.04.079
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641